ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
48 announcements with these filters
Novartis AG (promoter) sold its entire 70.68% stake, totaling 1,74,50,680 shares, in an off-market transaction valued at ₹1,376.89 Crore.
Novartis AG has formally reclassified from "Promoter" to "Public" shareholder category following its divestment and loss of control in Novartis India Limited.
Novartis AG completed the sale of 17.45 million shares to WaveRise and ChrysCapital, triggering a change in control and reclassification of the promoter to public category.
WaveRise Investments and others disclosed a substantial acquisition of shares in Novartis India Limited. The acquirers have become part of the promoter group of the company.
Novartis India Ltd reported revenue from operations of ₹103.8 Cr (+18.6% YoY) and net profit of ₹32.2 Cr (+16.7% YoY) for Q1 FY27.
Novartis India Ltd filed its quarterly shareholding pattern for the period ending June 30, 2026. The filing details the distribution of shares across promoter and public categories.
Axis Capital issued a post-offer advertisement for the open offer of Novartis India Limited. The acquirers proposed a ₹552.50 Crore acquisition but accepted only 40 shares.
Novartis India Ltd will hold a Board meeting on 23 July 2026. The meeting will consider the unaudited results for Q2 2026.
Acquirers launched an open offer for Novartis India at INR 860.64 per share. Public shareholders can tender shares from June 11 to June 24, 2026.
WaveRise Investments and others launched a ₹552.50 Crore open offer for 26% of Novartis India. The offer price is set at ₹860.64 per equity share.
Novartis India Limited filed its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report confirms overall regulatory adherence with no significant non-compliances noted.
Novartis India shareholders approved Ms. Gowree Gokhale's appointment as Independent Director for five years via postal ballot. The resolution passed with a 99.97% majority vote.
Novartis India Ltd reported revenue from operations of ₹90.5 Cr (+7.9% YoY) and net profit of ₹25.2 Cr (-14.0% YoY) for Q4 FY26.
Novartis India approved its audited financial results for the year ended March 31, 2026. The board declared an unmodified audit opinion, signaling stable financial reporting standards.
Novartis India Limited confirmed it does not qualify as a 'Large Corporate' for FY 2025-26 per SEBI debt-raising norms. The company reported zero outstanding long-term borrowings as of March 31, 2025. This routine regulatory disclosure indicates the company is not currently subject to mandatory incremental borrowing through debt securities.
Novartis India Limited has issued a Postal Ballot notice to seek shareholder approval for the appointment of Ms. Gowree Gokhale as a Non-Executive Independent Director for a five-year term. E-voting commences on April 17, 2026, and concludes on May 16, 2026. This follows the upcoming conclusion of Ms. Sandra Martyres' tenure.
Novartis India Ltd reported net profit of ₹16.1 Cr (-36.6% YoY) for Q3 FY26.
Novartis AG has entered into a Share Purchase Agreement to sell 1,74,50,680 equity shares, representing a 70.68% stake in Novartis India Ltd, to a consortium of acquirers including ChrysCapital. This transaction marks a significant change in corporate control and ownership of the company.